Daniel O'Day, Gilead CEO (Paras Griffin/Getty Images for ESSENCE)
February 26, 2024 06:51 AM EST
Deals
Pharma

Gilead bid against it­self in $4.3B deal for CymaBay, fil­ing shows

Kyle LaHucik

Senior Reporter

Gilead Sci­ences was the sole bid­der for liv­er dis­ease biotech CymaBay Ther­a­peu­tics and ul­ti­mate­ly hiked up its ini­tial pro­pos­al by $9.50 per share, ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times